Why Caribou Biosciences, Inc.’s (CRBU) Stock Is Down 6.44%
As of Tuesday, October 13, Caribou Biosciences, Inc.’s CRBU share price has dipped by 6.44%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
Commentary & Analysis
Why Caribou Biosciences, Inc.’s (CRBU) Stock Is Up 5.38%
As of Friday, October 09, Caribou Biosciences, Inc.’s CRBU share price has surged by 5.38%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Caribou Biosciences, Inc.’s (CRBU) Stock Is Down 11.86%
As of Thursday, October 08, Caribou Biosciences, Inc.’s CRBU share price has dipped by 11.86%, which has investors questioning if this is right time to buy.Michael Rose
Why Caribou Biosciences, Inc.’s (CRBU) Stock Is Down 22.74%
As of Thursday, October 08, Caribou Biosciences, Inc.’s CRBU share price has dipped by 22.74%, which has investors questioning if this is right time to buy.Tudor Pop
Why Caribou Biosciences, Inc.’s (CRBU) Stock Is Down 47.14%
As of Wednesday, October 07, Caribou Biosciences, Inc.’s CRBU share price has dipped by 47.14%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | CRBU | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $58.4 | $228.7 | 18% |
|
| Shares Out (Mil) | 101.0 | 53.9 | 62% |
|
| Institutional Ownership | 92.5% | 92.9% | 61% |
|
| Float (Mil) | 102.9 | 42.1 | 61% |
|
| Beta | 2.28 | 0.95 | 94% |
|
| Avg Daily Volume (000s) | 5,790 | 574 | 93% |
|
| Price Change (52-week) |
(80.7%) | 47.3% | 9% |
|
| Growth | CRBU | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (2.0%) | 13.6% | 13% |
|
| Net Income (5yr) | (34.0%) | (10.1%) | 12% |
|
| EPS (5yr) | 16.9% | 15.8% | 62 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 57.7% | (15.7%) | 95% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 4 | 4 | 3 | |
| Current EPS | ($0.263) | ($1.035) | ($0.897) | |
| Month Ago EPS | ($0.303) | ($1.175) | ($1.263) | |
| # Rev Up | 2 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.320) | ($1.247) | ($1.400) | |
| Year/Year Chg | 9.6% | (34.7%) | 5.9% | |
| Financials | CRBU | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $10 | $37 | 9% |
|
| Net Income (TTM) (Mil) | ($103) | ($44) | 11% |
|
| EPS (TTM) | ($1.075) | ($1.500) | 21% |
|
| Operating Cash Flow (TTM) (Mil) | ($96) | ($33) | 6% |
|
| Net Cash Flow (TTM) (Mil) | $1 | $2 | 45% |
|
| Long-Term Debt (Q1) (Mil) | $25 | $4 | 34% |
|
| Enterprise Value (Q1) (Mil) | $82 | $177 | 20% |
|
| Valuation | CRBU | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.59 | 2.24 | 12% |
|
| P/E | na | 20.0 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | CRBU | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (735.6%) | 66.9% | 0% |
|
| Net Margin | na | (73.7%) | na |
|
| ROA | (56.9%) | (47.0%) | 10% |
|
| ROE | (78.3%) | (54.1%) | 11% |
|
| Liabilities to Assets | 31.3% | 29.1% | 22% |
|
| F-Score | 3 | 2 | 18% |
|
Caribou Biosciences, Inc. did not pass any screens on 10/21/2026.
